InvestorsHub Logo
Followers 21
Posts 1996
Boards Moderated 0
Alias Born 11/26/2014

Re: Hank Kerchief post# 3318

Monday, 06/11/2018 10:16:50 AM

Monday, June 11, 2018 10:16:50 AM

Post# of 4163
Yes and the rat studies are not part of the Loe assisment.

But for now, TLD-1433’s contribution to our revenue/EBITDA forecasts is solely driven by our royalty revenue projections in BCG-refractory NMIBC only.
(The company has already began work with brain and lung cancers as well as others.)
Bladder cancer-targeted PDT TLD-1433 is a major value driver in our model
http://67.212.93.22/research/content/20170905TLT%20final.pdf

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141398929